Physician

Oncology

Dr. John A. Ellerton, MD

John A. Ellerton, MD works in the field of Oncology. John A. Ellerton is also published. He has 33 publications published. The lastest publication: "A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia ...' Dr. John A. Ellerton is registered with Medicare.

Publications

Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.
Erythroleukemia in a renal transplant recipient.
Prehospital use of ketamine in mountain rescue.
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia ...
Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized...
Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group.
Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia.
Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641.
Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
Retention of mouth-to-mouth, mouth-to-mask and mouth-to-face shield ventilation.
The impact of avalanche rescue devices on survival.
Basic life support ventilation in mountain rescue. Official recommendations of the International Commission for Mountain Emergency Medicine (ICAR MEDCOM).
Pattern and severity of injury in avalanche victims.
Comparison of mouth-to-mouth, mouth-to-mask and mouth-to-face-shield ventilation by lay persons.
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage ...
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Current status of medical training in mountain rescue in America and Europe.
Methoxyflurane as an analgesic for prehospital use at high altitude.
Fluid management in traumatic shock: a practical approach for mountain rescue. Official recommendations of the International Commission for Mountain Emergency Medicine...
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Immobilization and splinting in mountain rescue. Official Recommendations of the International Commission for Mountain Emergency Medicine, ICAR MEDCOM, Intended for Mo...
Equipment of medical backpacks in mountain rescue.
Medical standards for mountain rescue operations using helicopters: official consensus recommendations of the International Commission for Mountain Emergency Medicine ...
Risk assessment and emergency management of coronary heart disease at altitude.
Should helicopters have a hoist or ''long-line'' capability to perform mountain rescue in the UK?
Effects of training time and feedback on ventilation skills in lay rescuers.

Doctors Specialties

Oncology

Accepted Insurances

Education

Tufts Medical Center
McGill University Faculty of Medicine

Drug Facts

NPI NUMBER		1962585745
NPPES Provider LastName		ELLERTON
NPPES Provider FirstName		JOHN
NPPES Provider ZIPCode		890522648
NPPES Provider State		NV
Specialty Description		Medical Oncology
Total Claim Count		1130.0
Distinct Opioid Count		5.0
Opioid Claim Count		185.0
Percent Opioid Claims		16.37

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1962585745
Last Name Of The Provider	ELLERTON
First Name Of The Provider	JOHN
View All

Similar Doctors

	Dr. Brian D. Vicuna, MD This Doctor is OpenDoctor Recommended.
	Dr. Sreekanth Donepudi, MD This Doctor is OpenDoctor Recommended.
	Dr. Paul E. Michael, MD This Doctor is OpenDoctor Recommended.
	Dr. John C. Ruckdeschel, MD This Doctor is OpenDoctor Recommended. This doctor has more publications